Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer (Q34130816)

31 July 2017

title

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer (English)

1 reference

31 July 2017

Andrew C Hsieh

1

1 reference

31 July 2017

Davide Ruggero

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

11 August 2010

1 reference

31 July 2017

published in

Clinical Cancer Research

1 reference

31 July 2017

volume

16

1 reference

31 July 2017

issue

20

1 reference

31 July 2017

page(s)

4914-4920

1 reference

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

31 July 2017

cites work

1 reference

12 December 2020

Significance of eIF4E expression in skin squamous cell carcinoma

1 reference

12 December 2020

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

1 reference

12 December 2020

An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc

1 reference

12 December 2020

Oncogenic Ras and Akt Signaling Contribute to Glioblastoma Formation by Differential Recruitment of Existing mRNAs to Polysomes

1 reference

12 December 2020

Targeting the eIF4F translation initiation complex for cancer therapy

1 reference

12 December 2020

A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer

1 reference

12 December 2020

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

1 reference

12 December 2020

Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.

1 reference

12 December 2020

Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development

1 reference

12 December 2020

Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma

1 reference

12 December 2020

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

1 reference

12 December 2020

Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis

1 reference

12 December 2020

Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap

1 reference

12 December 2020

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance

1 reference

12 December 2020

Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.

1 reference

12 December 2020

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

1 reference

12 December 2020

Two forms of purified m7G-cap binding protein with different effects on capped mRNA translation in extracts of uninfected and poliovirus-infected HeLa cells

1 reference

12 December 2020

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis

1 reference

12 December 2020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

12 December 2020

Eukaryotic mRNA cap binding protein: purification by affinity chromatography on sepharose-coupled m7GDP

1 reference

12 December 2020

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

1 reference

12 December 2020

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

1 reference

12 December 2020

Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas

1 reference

12 December 2020

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

1 reference

12 December 2020

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

1 reference

12 December 2020

Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E

1 reference

12 December 2020

Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer

1 reference

12 December 2020

Competitive PCR to detect eIF4E gene amplification in head and neck cancer

1 reference

12 December 2020

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

1 reference

12 December 2020

Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

1 reference

12 December 2020

Detection of eIF4E gene amplification in breast cancer by competitive PCR.

1 reference

12 December 2020

Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G

1 reference

12 December 2020

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

1 reference

12 December 2020

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

1 reference

12 December 2020

Dissecting eIF4E action in tumorigenesis

1 reference

12 December 2020

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

1 reference

12 December 2020

The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation

1 reference

12 December 2020

Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities

1 reference

12 December 2020

Translational control in cancer.

1 reference

12 December 2020

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

1 reference

12 December 2020

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

1 reference

12 December 2020

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

1 reference

12 December 2020

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

1 reference

12 December 2020

The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro

1 reference

12 December 2020

Further evidence that ribavirin interacts with eIF4E

1 reference

12 December 2020

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

1 reference

12 December 2020

The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells

1 reference

12 December 2020

10.1158/1078-0432.CCR-10-0433

Identifiers

DOI

1 reference

31 July 2017

1 reference